Barclays Maintains Buy Rating and $383 PT on Cigna (CI)

Group 1 - Cigna Group is considered one of the most undervalued large-cap stocks currently available for investment, with a Buy rating and a price target of $383.00 from Barclays [1] - Goldman Sachs initiated coverage of Cigna with a Buy rating and a price target of $370, highlighting the significant underwriting downturn in the managed care industry and recommending increased exposure to the Medicare Advantage segment, with a projected margin recovery phase starting in 2026 [2] - Evernorth, Cigna's health services division, announced a new initiative aimed at lowering medication costs and improving transparency, which aligns with previous calls to address high brand-name drug costs and builds on its success in achieving low prices for generics [3]